Contrast Induced Nephropathy Global Clinical Trials Review, H1, 2019

GlobalData's clinical trial report, “Contrast Induced Nephropathy Global Clinical Trials Review, H1, 2019" provides an overview of Contrast Induced Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Contrast Induced Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

Pharming Group NV

Cumberland Pharmaceuticals Inc

General Electric Co

Daiichi Sankyo Co Ltd

Ischemix Inc

Inotek Pharmaceuticals Corp

Government of Alberta

CorMedix Inc

Baxter International ...

Pharming Group NV

Cumberland Pharmaceuticals Inc

General Electric Co

Daiichi Sankyo Co Ltd

Ischemix Inc

Inotek Pharmaceuticals Corp

Government of Alberta

CorMedix Inc

Baxter International Inc

Abbott Laboratories

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region ...

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials 16

Clinical Trials by Phase in G7 Countries 18

Clinical Trials in G7 Countries by Trial Status 19

Clinical Trials by E7 Countries: Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials 20

Clinical Trials by Phase in E7 Countries 22

Clinical Trials in E7 Countries by Trial Status 23

Clinical Trials by Phase 25

In Progress Trials by Phase 26

Clinical Trials by Trial Status 27

Clinical Trials by End Point Status 29

Subjects Recruited Over a Period of Time 30

Clinical Trials by Sponsor Type 31

Prominent Sponsors 32

Top Companies Participating in Contrast Induced Nephropathy Therapeutics Clinical Trials 34

Prominent Drugs 36

Clinical Trial Profile Snapshots 37

Appendix 127

Abbreviations 127

Definitions 127

Research Methodology 128

Secondary Research 128

About GlobalData 129

Contact Us 129

Source 130

List of Tables

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Region, 2019* 8

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019 ...

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Region, 2019* 8

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Contrast Induced Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12

Contrast Induced Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13

Contrast Induced Nephropathy Therapeutics Clinical Trials, North America, Top Countries, 2019* 14

Contrast Induced Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 15

Contrast Induced Nephropathy Therapeutics Clinical Trials, Central and South America, Top Countries, 2019* 16

Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2019* 17

Contrast Induced Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Contrast Induced Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2019* 21

Contrast Induced Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 23

Contrast Induced Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 24

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Phase, 2019* 26

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 27

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2019* 28

Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30

Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31

Contrast Induced Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 32

Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 33

Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 35

Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 37

List of Figures

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Region (%), 2019* 8

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019 ...

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Region (%), 2019* 8

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Contrast Induced Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12

Contrast Induced Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13

Contrast Induced Nephropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14

Contrast Induced Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 15

Contrast Induced Nephropathy Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019* 16

Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2019* 17

Contrast Induced Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Contrast Induced Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2019* 21

Contrast Induced Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 23

Contrast Induced Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 24

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Phase (%), 2019* 26

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 27

Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2019* 28

Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30

Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31

Contrast Induced Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 32

Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 33

Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 35

Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 37

GlobalData Methodology 129

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports